CG Oncology Q3 net loss $20.4M; cash $540.7M, runway through 2027

CG Oncology, Inc.

2024-Q3 EPS reported -$0.93 revenue$683,000

Net loss of $20.4M ($0.30 per share) vs $17.5M ($4.00) in Q3 2023.
Cash and securities $540.7M as of Sept 30, 2024; expects to fund operations through 2027.
R&D expenses $19.6M (up from $11.7M) driven by clinical trial and CMC costs.
G&A expenses $8.7M (up from $2.3M) due to personnel, professional fees, insurance.
Phase 3 BOND-003 cretostimogene results accepted as late-breaking abstract at SUO 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.